louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00568347: Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange
Official title: Evaluation of the Effects of Varying Doses of Inhaled Corticosteroids on Suppression of Total Exhaled, Bronchial, and Alveolar Nitric Oxide as Markers of Endogenous Inflammation in Patients With Moderate-to-severe COPD
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COPD
Keywords: chronic airflow obstruction
Lead sponsor: Gelb, Arthur F., M.D.
Sponsor class: INDIV
First posted: 2007-12-06
Enrollment: 39
Sex: ALL
Minimum age (years): 20
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: COPD

Brief summary: To evaluate the role of inhaled corticosteroids to suppress nitric oxide gas exchange in stable patients with moderate-to-severe COPD who are current non-smokers and not on oral corticosteroids.

Detailed description: Stable, non-smoking COPD patients not on oral corticosteroids will be randomized in single blinded study to evaluate nitric oxide gas exchange at baseline, and subsequent effects of fluticasone 100mcg/salmeterol 50mcg bid, and fluticasone 250mcg/salmeterol 50mcg bid. Primary end points will include measurements of nitric oxide at varying expiratory flow rates to calculate bronchial, and small airway/alveolar nitric oxide. Secondary end points will evaluate lung function. Exhaled nitric oxide production presumably reflects endogenous inflammation. Normal healthy, non-smoking controls will be used for comparison, with exhaled nitric oxide measured before and after 3 weeks of low dose inhlaed corticosteroids.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of copd
* Current non-smoker
* Not on oral corticosteroids
* Must be able to use Advair discus or salmeterol discus

Exclusion Criteria:

* Pregnancy
* Current smoker
* On corticosteroids
* Clinically unstable

Primary outcomes:
measure: total exhaled, bronchial, and small airway/alveolar nitric oxide
timeFrame: 3 months
Secondary outcomes:
measure: lung function
timeFrame: 3 months
Other outcomes:
Locations:
city: Lakewood
country: United States
facility: Arthur F Gelb MD
state: California
Study officials:
affiliation: Arthur F Gelb Medical Corporation
name: Arthur F Gelb, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gelb AF, Flynn Taylor C, Shinar C. Nitric Oxide gas exchange in COPD. Am J Respir Crit Care Med 2007; 174: A630.
citation: Gelb AF, George SC, Camacho F, Fraser C, Flynn Taylor C, Shakkottai S. Increased nitric oxide concentrations in the small airway of older normal subjects. Chest. 2011 Feb;139(2):368-375. doi: 10.1378/chest.10-1157. Epub 2010 Aug 12.
citation: Gelb AF, Flynn Taylor C, Krishnan A, Fraser C, Shinar CM, Schein MJ, Osann K. Central and peripheral airway sites of nitric oxide gas exchange in COPD. Chest. 2010 Mar;137(3):575-84. doi: 10.1378/chest.09-1522. Epub 2009 Oct 9.
Clinical trial NCT03143647: Magnesium and Platelet Function Testing
Official title: Influence of Therapeutic Magnesium on Platelet Function Testing
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Eclampsia Preeclampsia
Lead sponsor: Ziekenhuis Oost-Limburg
Sponsor class: OTHER
Collaborators: name: Maastricht University
First posted: 2017-05-08
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Females over 18 years of age (and younger or equal to 50 years of age) that meet the American Society of Anesthesiologists physical fitness scale 1 (non smoker, no or minimal alcohol use, ..)

Brief summary: Magnesium has built up the reputation of a 'natural calcium antagonist'. However, the exact effect of magnesium on coagulation and more specifically on platelet function is still disputed. An important discrepancy between in vivo and in vitro studies exists. Magnesium has thus been reported to antagonize platelets in some studies, and to stimulate platelets in other studies. Current evidence seems to point in the direction of a general antagonization of aggregation and coagulation.

Intravenous magnesium is often administered in pre-eclampsia as seizure prophylaxis. Therapeutic regimens usually consist of an intravenously administered loading dose (2-3 grams) and a maintenance infusion, targeting a plasma level of 2-3 mmol/L. Therapeutic drug monitoring is needed, as magnesium toxicity is an important concern.


Eligibility criteria: Inclusion Criteria:

* Signed Informed consent
* Over 18 years of age (and younger or equal to 50 years of age) and able to provide legally binding consent
* American Society of Anesthesiologists physical fitness scale 1 (non smoker, no or minimal alcohol use, ..)

Exclusion Criteria:

* Chronic disease
* Chronic medical therapy (other than oral contraception)
* Pregnancy
* ASA 2 or higher
* Known coagulation or aggregation disorders
* Use of COX-inhibitors in the last 10 days
* Contra-indications for venipuncture

Primary outcomes:
measure: PAC-t-UB test results
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Genk
country: Belgium
facility: Ziekenhuis Oost-Limburg
Study officials:
affiliation: Ziekenhuis Oost-Limburg
name: Dieter Mesotten, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04425447: Thoracic Interfascial Plane Block Versus Thoracic Paravertebral Block in Gynecomastia Surgery
Official title: Thoracic Interfascial Plane Block Versus Thoracic Paravertebral Block for Anesthesia in Gynecomastia Surgery: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gynecomastia
Thoracic Interfascial Plane Block
Thoracic Paravertebral Block
Anesthesia
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2020-06-11
Enrollment: 90
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The growing increase in the number of gynecomastia surgeries has resulted in an increased need for anesthetic techniques with improved pain reduction, safety, and fewer complications.

The aim of this work is to compare the efficacy of ultrasound guided thoracic interfascial plane block and ultrasound guided thoracic paravertebral block for anesthesia in gynecomastia surgery.

Detailed description: This prospective randomized open label clinical trial will be carried out on 90 male patients undergoing elective idiopathic gynecomastia surgery in Tanta University Hospitals.

Study design:

Patients will be randomly allocated into three equal groups by computer generated sequence through sealed opaque envelopes:

Group C: 30 patients will receive bilateral tumescent local anesthesia as a control group.

Group TPVB: 30 patients will receive bilateral US guided thoracic paravertebral block.

Group TIPB: 30 patients will receive bilateral US guided thoracic interfascial plane block.

Eligibility criteria: Inclusion Criteria:

* Aged ≥ 18 up to 65 years
* Male gender only
* ASA physical status I and II
* Weight 75-100 kg
* Duration of surgery ≤ 2 hours
* Scheduled for elective idiopathic gynecomastia surgery

Exclusion Criteria:

* Patient refusal.
* Uncooperative patients.
* Known hypersensitivity to local anesthetic (LA) (bupivacaine).
* Local infection at the site of injection (TPVB or TIPB).
* Coagulopathy.
* History of opioid abuse or chronic analgesic use.

Primary outcomes:
measure: The amount of intraoperative fentanyl requirement (mg)
timeFrame: 3 hours
Secondary outcomes:
measure: Degree of patient's satisfaction
timeFrame: 6 hours
Other outcomes:
measure: Amount of postoperative analgesic requirement (mg)
timeFrame: 24 hours
Locations:
city: Tanta
country: Egypt
facility: Tanta University Hospitals
state: ElGharbiaa
Study officials:
References:
Clinical trial NCT03221647: INF-α Innate Immune Response to Gliadin
Official title: A Gliadin Peptide Regulated the INF-α Immune Response in Celiac Small Intestine and in an En-terocyte Cell Line
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Celiac Disease
Keywords: Celiac Disease; P31-43; Loxorubine; TLR7.
Lead sponsor: Federico II University
Sponsor class: OTHER
First posted: 2017-07-18
Enrollment: 53
Sex: ALL
Minimum age (years): 2
Maximum age (years): 17
Standard ages: CHILD
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: For organ culture studies, biopsy fragments from duodenum were obtained from CD patients with villous atrophy on GCD, controls, affected by gastroesophageal reflux, and CD patients on GFD. Age range for all subjects was 2-17 years.

Brief summary: Background \& Aims The enteropathy in Celiac Disease (CD) is due the adaptive and to the innate immune response to gliadin peptides. Gliadin peptide P31-43 activates innate immune response and interferes with vesicular trafficking. Type 1 interferons (INFs) and viral infections play a role in CD pathogenesis. In this paper investigators investigated the role of P31-43 in the activation of the INF-α pathway.

Methods Small intestinal biopsies of CD patients both with active disease on gluten containing diet (GCD) and in remission phase of the disease on a gluten free diet (GFD) and controls were analyzed before and after culture with P31-43. The levels of toll like receptor 7 (TLR7), myeloid differentiation primary response 88 (MyD88), myxovirus resistance protein 1 (MxA) and nuclear factor-κB (NF-κB) proteins and INF-α mRNA was analyzed in intestinal biopsies.

Detailed description: Intestinal biopsies from CD patients and controls were obtained after EGDS performed during routine analysis. The biopsies were immediately immersed in culture medium (Dulbecco's modified medium, DMEM) in a falcon tube and kept for 16h at 37 C before cultivation. Biopsies were cultivated as described in Barone MV1, Caputo I, Ribecco MT, Maglio M, Marzari R, Sblattero D, Troncone R, Auricchio S, Esposito C. Humoral immune response to tissue transglutaminase is related to epithelial cell proliferation in celiac disease. Gastroenterology. 2007,132(4):1245-53.

Eligibility criteria: Inclusion Criteria:

biopsy fragments from duodenum were obtained from CD patients with villous atrophy on GCD, controls, affected by gastroesophageal reflux, and CD patients on GFD.

Exclusion Criteria:

other inflammatory intestinal diseases

Primary outcomes:
measure: Measurement of Mxa and INF alpha proteins in CD biopsies compared to controls
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Naples
country: Italy
facility: Riccardo Troncone
Study officials:
affiliation: Federico II University
name: M.Vittoria Barone
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00862147: Effectiveness Study of the International Child Development Program
Official title: The Effect of the International Child Development Program - A Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Psychosocial Functioning
Child Development
Keywords: Child psychosocial Functioning
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: The Research Council of Norway
First posted: 2009-03-16
Enrollment: 35
Sex: ALL
Minimum age (years): 4
Maximum age (years): 4
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The objective of this study is to evaluate the effect of the International Child Development Program (ICDP). Research questions to be answered:

1. Does the ICDP affect children's psychosocial functioning compared to treatment as usual?
2. Does the ICDP change parent-child interaction?


Eligibility criteria: Inclusion Criteria:

* SDQ \>/= 9, subjective treatment need

Exclusion Criteria:

* Already in treatment

Primary outcomes:
measure: psychosocial functioning
timeFrame: study terminated
Secondary outcomes:
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: Norwegian University of Science and Technology
Study officials:
affiliation: Norwegian University of Science and Technology
name: Lars Wichstrom
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06502847: The Role of Breastmilk and Serum Exosomes in Neonatal Jaundice Due to ABO Incompatibility
Official title: The Role of Breastmilk and Serum Exosome Profile in Prediction of the Severity and Treatment Requirement of Neonatal Jaundice Due to ABO Incompatibility
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Neonatal Jaundice From Other Specified Causes
ABO Incompatibility
ABO Hemolytic Disease
Lead sponsor: Kanuni Sultan Suleyman Training and Research Hospital
Sponsor class: OTHER
First posted: 2024-07-16
Enrollment: 45
Sex: ALL
Maximum age (years): 28
Standard ages: CHILD
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: It is planned to include a total of 45 babies in the study, including healthy babies (n=15) in the first group, babies who developed jaundice due to ABO incompatibility but did not need treatment (n=15) in the second group, and babies who developed jaundice due to ABO incompatibility and needed treatment (n=15) in the third group.

Brief summary: Neonatal jaundice is a major global health issue that can lead to serious complications and even death if not promptly treated. ABO incompatibility is a common cause of pathological neonatal jaundice, but there are currently no specific tests to predict its severity or progression. This project aims to study the role of exosomes in the diagnosis and treatment of newborn jaundice, focusing on their impact on infants with ABO incompatibility. The study will take place at a reference neonatal intensive care unit, involving 45 infants. Serum and breast milk samples will be collected and analyzed to determine any relationships and possible correlations.


Eligibility criteria: Inclusion Criteria:

* Newborns who are needed treatment for neonatal jaundice due to ABO incompatibility
* Newborns who are admitted to the study center due to ABO hemolytic disease
* Newborns with ABO incompatibility
* Healthy newborns
* Healthy mothers

Exclusion Criteria:

* Lack of informed consent
* Congenital abnormalities
* Maternal Liver diseases
* Neonatal liver diseases
* Sepsis
* Neonatal jaundice due to the causes other than ABO incompatibility
* Acute or chronic disease state in newborn
* Maternal acute or chronic disease
* Medication or substance use effecting liver functions

Primary outcomes:
measure: Number of the participant who Need for Treatment
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01850147: Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen
Official title: Study of Efficacy and Safety of Sequential Low-dose Sunitinib With Chemotherapy in Advanced Non-small Cell Lung Cancer After Failure of Conventional Regimen
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Cancer
Lung Cancer
Keywords: sunitinib
chemotherapy
non-small cell lung cancer
NSCLC
Lead sponsor: ChineseAMS
Sponsor class: UNKNOWN
First posted: 2013-05-09
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether sequential application of low-dose short-term sunitinib and chemotherapy is effective in the treatment of non-small cell lung cancer after failure of conventional therapy. Safety of this regimen will also be evaluated.


Eligibility criteria: Inclusion Criteria:

* Histologic or cytologic diagnosis of stage IIIB/IV NSCLC
* ECOG PS: 0,1
* Unidimensional or bi-dimensional measurable disease
* Receive prior treatment including first-line platinum-based chemotherapy, standard second-line chemotherapy and 1 EGF/EGFR inhibitor
* Evidence of disease progression
* Life expectancy \>12 weeks
* Neutrophils \> 1.5 109/l, Platelets \> 100 109/l, Hemoglobin \> 9g/dl, Total bilirubin \< 1.5 UNL, AST (SGOT) and ALT (SGPT) \< 2.5 UNL, Alkaline phosphatases \< 5 UNL, Creatinine \< 1 UNL

Exclusion Criteria:

* Pre-existing hemoptysis of a severity \> grade 3 by NCI CTCAE criteria within 4 weeks prior to study entry
* Uncontrolled hypertension
* CHF, angina or arrhythmias
* LVEF \< 1 UNL
* Existing a second malignancy within 5 years
* Infected with HIV

Primary outcomes:
measure: progression-free survival
timeFrame: up to 2 years
Secondary outcomes:
measure: overall survival
timeFrame: up to 2 years
measure: disease control rate
timeFrame: up to 6 months
measure: Safety
timeFrame: up to 2 years
Other outcomes:
Locations:
city: Beijing
country: China
facility: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study officials:
References:
Clinical trial NCT01755247: A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers
Official title: A Phase One, Single-Center, Open-Label, Randomized, Parallel Group, 3 Day Study Evaluating the Safety and Cutaneous Tolerability of NVN10000 Topical Gel in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Acne Vulgaris
Keywords: acne
Lead sponsor: Novan, Inc.
Sponsor class: INDUSTRY
First posted: 2012-12-24
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Phase I, Single-Center, Open-Label, Randomized, Parallel Group, 3 Day Study Evaluating the Safety and Cutaneous Tolerability of NVN1000 Topical Gel in Healthy Volunteers

Detailed description: This is a 3 day study to assess safety and tolerability of a new topical gel product, NVN1000 with and without the application of a commercially available moisturizer in approximately 15 healthy subjects. The test product will be applied to the forehead of healthy volunteers once daily for 3 days. One group of subjects will have a moisturizer applied to the same area 15 minutes after the test gel was applied and one group of subjects will be treated with the gel vehicle which does not contain the active product. The hypothesis is that the application of moisturizer will not effect safety or local tolerability.

Eligibility criteria: Inclusion Criteria:

* Healthy Male and Females \> 18 years of age
* High degree of fluorescence of facial skin under Wood's lamp

Exclusion Criteria:

* Acute or chronic skin disorders
* Topical or systemic antibiotics within 4 weeks of study enrollment
* Use of medication that increases risk of methemoglobinemia or influences P. acnes counts
* Subjects with medical illnesses, anemia, elevated methemoglobin
* Women who are pregnant, nursing or planning a pregnancy

Primary outcomes:
measure: Cutaneous tolerability
timeFrame: 3 days
Secondary outcomes:
measure: Safety comparison
timeFrame: 3 Days
Other outcomes:
measure: Propionibacterium acnes counts
timeFrame: 3 days
Locations:
city: Broomall
country: United States
facility: KGL, Inc
state: Pennsylvania
Study officials:
affiliation: KGL, Inc.
name: James J Leyden
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02894047: Study of the Influence of the Expression of the Calcium-sensitive Receptor (CaSR) by Monocytes in the Synovial Liquid on Structural Alterations in Patients Diagnosed With Rheumatoid Arthritis in the Previous Two Years
Official title: Study of the Influence of the Expression of the Calcium-sensitive Receptor (CaSR) by Monocytes in the Synovial Liquid on Structural Alterations in Patients Diagnosed With Rheumatoid Arthritis in the Previous Two Years
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Arthritis, Rheumatoid
Keywords: calcium-sensitive receptor
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2016-09-09
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: - Patients consulting in the Department of Rheumatology at Amiens University Hospital

Brief summary: Rheumatoid arthritis (RA) is the most frequent form of chronic inflammatory rheumatism in adults. The erosive damage influences the functional prognosis in patients with RA. At present, there are no sufficiently sensitive and specific predictive markers of erosive damage.


Eligibility criteria: Inclusion Criteria:

* Patients consulting in the Department of Rheumatology at Amiens University Hospital
* Age ≥ 18
* RA meeting the 2010 ACR/EULAR criteria
* Less than 2 years of RA progression
* Effusion in at least 1 joint

Exclusion Criteria:

* Inability to give informed consent
* Ongoing pregnancy
* Previous treatment with an anti-osteoporosis medication
* Intra-articular corticoid or hyaluronic acid injection in the previous 6 months
* Coagulation disorders preventing arthrocentesis
* Incarceration or legal guardianship

Primary outcomes:
measure: CaSR expression rate level on synovial monocytes
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens
Study officials:
affiliation: CHU Amiens
name: Vincent GOEB, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04654247: Endoscopic Quality Improvement System Study
Official title: A Prospective, Single-center Study Evaluating the Effectiveness of Endo.Adm in Improving the Quality of Gastrointestinal Endoscopy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adenoma Colon
Gastric Precancerous Condition
Lead sponsor: Renmin Hospital of Wuhan University
Sponsor class: OTHER
First posted: 2020-12-04
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: We intend to develop intelligent quality control and management software based on the work of digestive endoscopic artificial intelligence in the Department of Gastroenterology, Wuhan University Renmin Hospital, to accurately and comprehensively assess the quality of gastrointestinal endoscopy and to provide a practical basis for improving the quality of digestive endoscopy in our endoscopic center.


Eligibility criteria: Inclusion Criteria:

Endoscopist:

1. Endoscopist with more than one year experience in gastrointestinal mirror operation;
2. Willing to further improve endoscopic quality through Endo.Adm feedback;
3. Ability to read, understand and sign informed consent; The investigator believes that the subject understands the flow of the clinical study and is willing and able to complete all research procedures and follow-up visits in conjunction with the research process.

Exclusion Criteria:

Endoscopist:

1. Have participated in other clinical trials;
2. Frequently attending in academic conference which is difficult to ensure the number of endoscopic operations;
3. Endoscopist who were either not present for both parts (phase1 and phase2) of the study.

Patients:

Colonoscopy:

1. Polyposis syndromes
2. Lumen obstruction
3. History of colorectal surgery
4. History of colorectal surgery

Gastroscopy:

1. Obstruction
2. History of gastric surgery

Primary outcomes:
measure: Adenoma detection rate
timeFrame: 3 Months
measure: Gastric precancerous detection rate
timeFrame: 3 Months
Secondary outcomes:
measure: Adcanced ADR
timeFrame: 3 months
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Renmin Hospital of Wuhan University
state: Hubei
Study officials:
References: